Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TriSalus Life Sciences, Inc. before investing.

In this article, we go over a few key elements for understanding TriSalus Life Sciences, Inc.’s stock price such as:

• TriSalus Life Sciences, Inc.’s current stock price and volume
• Why TriSalus Life Sciences, Inc.’s stock price changed recently
• Upgrades and downgrades for TLSI from analysts
• TLSI’s stock price momentum as measured by its relative strength

About TriSalus Life Sciences, Inc. (TLSI)

Before we jump into TriSalus Life Sciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Want to learn more about TriSalus Life Sciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TriSalus Life Sciences, Inc..

TriSalus Life Sciences, Inc.’s Stock Price as of Market Close

As of April 17, 2026, 4:00 PM, CST, TriSalus Life Sciences, Inc.’s stock price was $4.650.

TriSalus Life Sciences, Inc. is up 3.56% from its previous closing price of $4.490.

During the last market session, TriSalus Life Sciences, Inc.’s stock traded between $4.470 and $4.770. Currently, there are approximately 46.84 million shares outstanding for TriSalus Life Sciences, Inc..

TriSalus Life Sciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

TriSalus Life Sciences, Inc. Stock Price History

TriSalus Life Sciences, Inc.’s (TLSI) price is currently up 16.25% so far this month.

During the month of April, TriSalus Life Sciences, Inc.’s stock price has reached a high of $4.770 and a low of $3.620.

Over the last year, TriSalus Life Sciences, Inc. has hit prices as high as $7.950 and as low as $3.420. Year to date, TriSalus Life Sciences, Inc.’s stock is down 33.38%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused TriSalus Life Sciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 17, 2026, there was 1 analyst who downgraded TriSalus Life Sciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate TriSalus Life Sciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TriSalus Life Sciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TriSalus Life Sciences, Inc. (TLSI) by visiting AAII Stock Evaluator.

Relative Price Strength of TriSalus Life Sciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 17, 2026, TriSalus Life Sciences, Inc. has a weighted four-quarter relative price strength of -11.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how TriSalus Life Sciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TriSalus Life Sciences, Inc. Stock Price: Bottom Line

As of April 17, 2026, TriSalus Life Sciences, Inc.’s stock price is $4.650, which is up 3.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TriSalus Life Sciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.